Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

An epstein-barr-virus vaccine

A Barr virus and vaccine technology, applied in the direction of viruses, viral peptides, antiviral agents, etc., can solve the problems that it cannot be applied to humans, cannot trigger EBV-specific immune cells, and CD4+ cells cannot be regarded as vaccines, etc.

Inactive Publication Date: 2013-09-25
亥姆霍兹慕尼黑中心德国研究健康与环境有限责任公司
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the potential presence of oncogenes in DNA lacking transforming EBV DNA and the presence of transforming proteins in VLPs, they cannot be used in humans for safety and ethical reasons
Furthermore, the resulting CD4+ cells cannot be considered an effective vaccine, let alone used as a prophylactic vaccine, since CD4+ cells are generated only from EBV-positive donors, and they cannot elicit EBV-specific immunity in EBV-naive individuals cell

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • An epstein-barr-virus vaccine
  • An epstein-barr-virus vaccine
  • An epstein-barr-virus vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0100] Example 1 : 293-VII+ cells release VLPs when induced to lack viral DNA but contain various EBV proteins

[0101] The inventors have recently described the construction of two helper cell lines for the encapsulation of EBV-derived vectors into recombinant virus particles (Delecluse et al., 1999; Hettich et al., 2006). These cell lines contain an EBV helper genome that lacks terminal repeats (TRs), but instead contains the gfp gene for the packaging signal of this virus. Thus, these helper cell genomes cannot be packaged into viral particles, but instead deliver in trans all the proteins required for packaging a suitable viral vector as well as assembly and release of recombinant and infectious EBV particles. The first generation cell line, TR-2, contains an additional complete EBV genome that retains the full transformation capacity of primary human B-cells (Delecluse et al., 1999). To deal with the rare irrational packaging of helper cell genomes and the unintended r...

Embodiment 2

[0104] Example 2: 293-VII+-VLP has EBV-like B-cell tropism

[0105] One protein found to be incorporated into the VLP is gp350 / 220, the major viral envelope protein that mediates virion binding to human B-lymphocytes by interacting with CD21. Therefore, the inventors wanted to elucidate whether VLPs have a B-cell tropism similar to wild-type EBV. To do this, they incubated freshly isolated PBMCs overnight with concentrated VII+ VLPs and analyzed VLP binding by FACS. For these experiments, they took advantage of the fact that enhanced GFP expressed from the genome of VII+ helper cells was also incorporated into VLPs. as in Figure 3a As shown in , binding of VLPs was restricted to CD21+ cells, most likely B-cells, as judged by the fact that only CD21+ cells became GFP-positive. In contrast, VLP binding to CD21-negative cells could not be observed. To study the interaction of VLPs with B-cells in more detail, the inventors performed confocal microscopy on VLP-cultured PBMC...

Embodiment 3

[0107] Example 3 : VII+-VLPs induce neutralizing EBV-specific antibodies in naive hosts

[0108] The results of the previous sections demonstrate the potential of VLPs to stimulate EBV-specific awakening of immune responses. In the next series of experiments, the inventors therefore evaluated whether VLPs were also able to induce EBV-specific immune responses in naive hosts in vivo, which is of course a prerequisite for prophylactic vaccines. For this purpose, the inventors vaccinated BALB / C mice twice intraperitoneally with 10 μg VLP (n=4) over a period of 14 days and immunized control mice with the same amount of exosomes isolated from the 293 supernatant. Rats (n=2). Four weeks after the second immunization, sera were collected and analyzed for the presence of EBV-specific antibodies, and splenocytes were tested for EBV specificity. To this end, the inventors coated a collection of 96-well plates with serial lysates of HEK293 cells that had been transiently transfected ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a vaccine comprising a particle, said particle comprising (i) at least one Epstein-Barr virus (EBV) structural polypeptide, (ii) at least one EBV lytic polypeptide, (iii) membrane lipids, said particle being devoid of EBV DNA, wherein (a) the B-cell transformation capacity of one or more EBV polypeptides required for B-cell transformation as comprised in said particle is disabled while their immunogenicity is maintained; and / or (b) said particle is devoid of one or more EBV polypeptides required for B-cell transformation. Furthermore, the invention relates to a method for generating a particle, to a cell obtained in the method of the invention, a kit comprising the vaccine or the particle generated according to the method of the invention. Also, the invention relates to the use of the vaccine or the particle generated according to the method of the invention for generating CD8+ cells specific for an EBV antigen.

Description

technical field [0001] The present invention relates to vaccines comprising particles comprising (i) at least one Epstein-Barr virus (EBV) structural polypeptide, (ii) at least one EBV lytic polypeptide, (iii) membrane lipid Classes wherein the particle lacks EBV DNA, wherein (a) the B-cell transforming capacity of one or more EBV polypeptides required for B-cell transformation as contained in the particle is inactivated while its immunogenicity is maintained and / or (b) the particle lacks one or more EBV polypeptides required for B-cell transformation. Furthermore, the present invention relates to methods of producing particles, to cells obtained in the methods of the invention, to kits comprising said vaccines or particles produced according to the methods of the invention. Furthermore, the invention relates to the use of said vaccine or particles produced according to the method of the invention for the generation of CD8+ cells specific for EBV antigens. [0002] Throughou...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/245C12N7/04C12N7/02
CPCA61K39/12A61K39/245A61K2039/5258A61P31/22A61P35/00C07K2317/569C12N7/00C12N2710/16223C12N2710/16234C12N2710/16252A61K2039/57A61K2039/575C07K14/005C12N2710/16262C12N2710/16271
Inventor 罗曼娜·鲁伊斯吉尔伯特·赖斯巴赫沃尔夫冈·哈默施密特赖因哈德·蔡德勒
Owner 亥姆霍兹慕尼黑中心德国研究健康与环境有限责任公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com